Data from Codiak's exoASO™-STAT6 Preclinical Development
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE,...
Source: globenewswire.com
Stay updated with breaking news from Nasdaq Cdak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE,...
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on...